acarbose: receipt-backed evidence fronts

Source literature boundary memo

Research question

Across retrieved fact-level receipts for acarbose, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

Selection criteria

The source-literature fallback selected acarbose because the domain snapshot exposed enough fact-backed, topic-overlapping papers. The fallback requires at least five verifiable source papers with fact-level receipts, distinct title keys, and a non-repeated report series before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

Boundary map

• The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome [primary; 2019] doi:10.1128/msphere.00528-18
  • Finding: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure.
  • Population: mice fed high-starch diet
  • Intervention/exposure: acarbose at 400 ppm
  • Comparator: control without acarbose
• Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats. [primary; 2013] doi:10.1371/journal.pone.0079697
  • Finding: 8-week treatment with acarbose significantly decreased fasting blood glucose.
  • Population: diabetic rats
  • Intervention/exposure: acarbose
  • Comparator: diabetic group
• Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone [primary; 2020] doi:10.14336/ad.2019.0621
  • Finding: The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005)
  • Population: new-onset type 2 diabetes patients
  • Intervention/exposure: acarbose
  • Comparator: never users of acarbose
• Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study [primary; 2014] doi:10.3346/jkms.2014.29.1.90
  • Finding: The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups.
  • Population: type 2 diabetes patients inadequately controlled with basal insulin treatment
  • Intervention/exposure: acarbose and voglibose
• Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. [primary; 2014] doi:10.1111/acel.12170
  • Finding: Acarbose increased male median lifespan by 22% (P < 0.0001)
  • Population: genetically heterogeneous mice
  • Intervention/exposure: acarbose
  • Comparator: control

Source synthesis

This receipt-backed scoping note has one bounded signal: acarbose shows context-dependent, not convergent, associations across this 5-source primary bundle (2013-2020). Grouped by direction, directionally favorable: 8-week treatment with acarbose significantly decreased fasting blood glucose; The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose... | other/mixed: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure; The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005). The source facts cover 5 population context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Concrete source-level examples: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure; 8-week treatment with acarbose significantly decreased fasting blood glucose; The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005).

Directional grouping

• other/mixed: The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome — a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure.
• directionally favorable: Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats. — 8-week treatment with acarbose significantly decreased fasting blood glucose.
• other/mixed: Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone — The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005)
• directionally favorable: Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study — The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups.
• other/mixed: Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. — Acarbose increased male median lifespan by 22% (P < 0.0001)

Candidate moderators are population or indication, endpoint, comparator, and study design/evidence type; these dimensions explain why the receipts should be read as divergent evidence fronts, not one pooled effect.

Context separation

The selected receipts group because each carries a fact-level extraction for acarbose; they separate by context (animal model and human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.

Boundary limits

Source-literature boundary for acarbose: the listed sources define separate evidence fronts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources. The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.

Next gaps

A stronger memo needs one matched PICO, for example: population=mice fed high-starch diet; intervention/exposure=acarbose at 400 ppm; comparator=control without acarbose; outcome=one named clinical endpoint. If acarbose is promoted beyond a scoping note, the next run should select sources sharing one context family rather than mixing animal model and human clinical/observational.